Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination

Emory University

Status: Invitation-only

Conditions: Yellow Fever Vaccine

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT01244802

IRB00002834

U19AI057266 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The objective of this study is to study immune memory generated against the yellow fever (YFV) vaccine in participants who have previously received the vaccine. Volunteers will not receive vaccine shots; only immune responses to previous yellow fever vaccination will be studied. The study involves one or multiple blood draws.

Full description

The goal of this study is to characterize immune memory in humans who have previously received yellow fever vaccine. The project is designed to study the magnitude and persistence of both humoral, and cell-mediated immune memory generated post-vaccination. Since aging has an effect on the immune system (eg. decreased thymic output, replacement of hematopoietic cells in the bone marrow with adipocytes), the researchers will analyze the young adults (aged 18-45 years) and the older vaccinees (55 years or older) in separate groups.

The specific aims of the study are to:

• Determine the phenotypic and functional characterization of memory T cell responses to yellow fever vaccination
• Determine neutralizing antibody titer after yellow fever vaccination

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Able to understand and give informed consent
• Age 18-45 years (Group 1) or 55 years and above (Group 2) at the time of yellow fever vaccination
• Documentation (international certificate of vaccination (yellow card) or medical record) indicating receipt of yellow fever vaccine.

Exclusion criteria

• Recipient of any vaccines within 30 days before the study visit (not applicable to older adults)
• History of a progressive and severe chronic medical condition resulting in impaired immunity (such as diabetes, kidney or liver dysfunction)
• Required use of immunosuppressive medications
• Reporting HIV, Hepatitis B (surface antigen positive) or Hepatitis C infections (antibody positive) on the medical/health history form
• Recipient of a blood product or immune globulin product within 42 days of study visit
• Reporting pregnancy

Trial design

300 participants in 2 patient groups

Group 1: 18 to 45 years of age

Description:

Between the ages of 18 and 45 at the time of yellow fever vaccination

Group 2: 55 years of age and above

Description:

Aged 55 or greater at the time of yellow fever vaccination